View Future GrowthPerspective Therapeutics 過去の業績過去 基準チェック /06Perspective Therapeuticsの収益は年間平均-62%の割合で減少していますが、 Biotechs業界の収益は年間 増加しています。収益は年間29.1% 50.6%割合で 減少しています。主要情報-62.02%収益成長率-29.51%EPS成長率Biotechs 業界の成長17.04%収益成長率-50.62%株主資本利益率-50.06%ネット・マージン-11,723.42%次回の業績アップデート11 May 2026最近の業績更新Perspective Therapeutics, Inc. to Report Q1, 2026 Results on May 11, 2026Apr 25Full year 2025 earnings: EPS and revenues miss analyst expectations Mar 18Perspective Therapeutics, Inc. to Report Fiscal Year 2025 Results on Mar 16, 2026Feb 17Third quarter 2025 earnings: Revenues exceed analysts expectations while EPS lags behind Nov 12Perspective Therapeutics, Inc. to Report Q3, 2025 Results on Nov 10, 2025Oct 24Second quarter 2025 earnings: EPS and revenues exceed analyst expectations Aug 14すべての更新を表示Recent updatesPerspective Therapeutics, Inc. to Report Q1, 2026 Results on May 11, 2026Apr 25Perspective Therapeutics Inc Presents Updated Interim Data of [212Pb]VMT-a-NET in Ongoing Phase 1/2A Clinical TrialApr 21Perspective Therapeutics, Inc., Annual General Meeting, May 27, 2026Apr 17New major risk - Revenue size Mar 18Full year 2025 earnings: EPS and revenues miss analyst expectations Mar 18Perspective Therapeutics, Inc. to Report Fiscal Year 2025 Results on Mar 16, 2026Feb 17New major risk - Shareholder dilution Feb 04Perspective Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $174.99337 million.Feb 03+ 1 more updateNew major risk - Share price stability Jan 29Perspective Therapeutics, Inc. Provides Clinical UpdatesJan 13Price target decreased by 8.1% to US$12.31 Dec 04Perspective Therapeutics Announces Acceptance of VMT-a-NET Data for Presentation At the Asco Gastrointestinal Cancers SymposiumDec 04Price target decreased by 8.0% to US$12.61 Nov 21Third quarter 2025 earnings: Revenues exceed analysts expectations while EPS lags behind Nov 12Perspective Therapeutics, Inc. to Report Q3, 2025 Results on Nov 10, 2025Oct 24Perspective Therapeutics, Inc. Announces First Patient Dosed with PSV359 in the Second Cohort of a Phase 1/2a Study in Patients with FAP-A Positive Solid TumorsOct 03High number of new and inexperienced directors Oct 01Perspective Therapeutics, Inc. Progresses Dose Finding for [212Pb)VMT01 in Combination with Nivolumab in Its Ongoing Phase 1/2a Study of MC1R-Positive Metastatic MelanomaSep 15Perspective Therapeutics Announces Chief Financial Officer ChangesSep 04Perspective Therapeutics, Inc. Appoints Maya Martinez-Davis to Board of Directors and as A Member of the Compensation Committee of the Board and the Nominations Committee, Effective September 03, 2025Sep 03Second quarter 2025 earnings: EPS and revenues exceed analyst expectations Aug 14Perspective Therapeutics Announces Acceptance of VMT-a-NET Data for Presentation at the ESMO Congress 2025Jul 25Perspective Therapeutics, Inc. to Report Q2, 2025 Results on Aug 13, 2025Jul 15Perspective Therapeutics, Inc.(NYSEAM:CATX) dropped from Russell 3000E Growth IndexJun 30+ 4 more updatesPerspective Therapeutics, Inc. Commences Recruitment for VMT-a-NET in the Third Dose Escalation Cohort of its Ongoing Phase 1/2a Clinical TrialJun 22Perspective Therapeutics, Inc. Highlights Updated Interim Data from its Ongoing Phase 1/2a Clinical Trial of [212Pb]VMT-a-NET at the 2025 ASCO Annual MeetingMay 31Consensus revenue estimates increase by 27% May 19First quarter 2025 earnings: EPS and revenues exceed analyst expectations May 13Perspective Therapeutics, Inc. Announces First Patient Dosed with Psv359 in A Phase 1/2A Study in Patients with Fap-A Positive Solid TumorsApr 30New minor risk - Share price stability Apr 22Perspective Therapeutics, Inc., Annual General Meeting, May 28, 2025Apr 18Perspective Therapeutics, Inc. to Report Q1, 2025 Results on May 12, 2025Apr 17Perspective Therapeutics, Inc. Announces First Patient Dosed with212Pb)VMT01 Monotherapy at 1.5 mCi in a Phase 1/2a Study of MC1R-Positive Metastatic MelanomaApr 13Consensus revenue estimates fall by 26% Apr 02Independent Director recently bought US$132k worth of stock Apr 02Full year 2024 earnings: EPS and revenues miss analyst expectations Mar 27Price target decreased by 9.7% to US$15.58 Mar 19Perspective Therapeutics, Inc. Announces First Patient Dosed with Cm1R-Positive Metastatic MelanomaMar 18Perspective Therapeutics, Inc. to Report Fiscal Year 2024 Results on Mar 26, 2025Feb 21Perspective Therapeutics, Inc. Continues to Pursue Dose Escalation of [212Pb) Vmt-A-Net in Its Ongoing Phase 1/2A Clinical Trial Based on Updated Interim Data Presented At the 2025 Asco Gastrointestinal Cancers SymposiumJan 24Perspective Therapeutics Announces Chief Financial Officer ChangesJan 06Independent Director recently bought US$100k worth of stock Dec 08CEO & Director recently bought US$100k worth of stock Nov 27New major risk - Revenue and earnings growth Nov 25Price target decreased by 15% to US$18.17 Nov 24Perspective Therapeutics, Inc. Announces Initial Results from its Ongoing Phase 1/2a Clinical Trial of [212Pb] VMT-a-NetNov 21New minor risk - Share price stability Nov 18Third quarter 2024 earnings: EPS and revenues exceed analyst expectations Nov 14New major risk - Revenue size Nov 13Perspective Therapeutics, Inc. to Report Q3, 2024 Results on Nov 12, 2024Oct 31Perspective Therapeutics Begins Shipping Investigational Products from Radiopharmaceutical Manufacturing Facility in Somerset, New JerseyOct 16Perspective Therapeutics to Advance Investigation of Potential First-In-Class Radiopharmaceutical Therapy (212Pb)Vmt01 Based on Data Presented At the 21St International Congress of the Society for Melanoma ResearchOct 11Perspective Therapeutics Grants Fast Track Designation for VMT01 for the Diagnosis and Treatment of MC1R-Positive MelanomaSep 05Consensus revenue estimates increase by 51%, EPS downgraded Aug 20Perspective Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $49.868808 million.Aug 14+ 1 more updateSecond quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind Aug 13Perspective Therapeutics, Inc. to Report Q2, 2024 Results on Aug 12, 2024Jul 22CFO & Co-Principal Financial Officer recently bought US$177k worth of stock Jun 19CEO & Director recently bought US$117k worth of stock Jun 14Perspective Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $79.998535 million.May 25First quarter 2024 earnings: EPS and revenues exceed analyst expectations May 17Perspective Therapeutics, Inc. to Report Q1, 2024 Results on May 15, 2024May 03+ 1 more updateNew minor risk - Profitability Apr 09No longer forecast to breakeven Apr 09Full year 2023 earnings released: US$0.14 loss per share (vs US$0.10 loss in FY 2022) Mar 28Perspective Therapeutics, Inc., Annual General Meeting, May 31, 2024Mar 26Perspective Therapeutics, Inc. announced that it has received $87.409482 million in funding from Lantheus Holdings, Inc.Mar 07Perspective Therapeutics, Inc. announced that it expects to receive $87.409482 million in funding from Lantheus Holdings, Inc. and other investorsMar 06Perspective Therapeutics, Inc. (NYSEAM:CATX) completed the acquisition of Radiopharmaceutical Manufacturing Facility in Somerset, New Jersey from Progenics Pharmaceuticals, Inc.Mar 05Perspective Therapeutics, Inc. Introduces Pre-Targeting Theranostic Technology PlatformFeb 02Chief Medical Officer recently bought US$140k worth of stock Jan 28Forecast to breakeven in 2026 Jan 26Perspective Therapeutics, Inc. announced that it has received $20.846671 million in funding from Lantheus Alpha Therapy, LLCJan 23Perspective Therapeutics, Inc. announced that it expects to receive $20.8 million in fundingJan 19+ 1 more updatePerspective Therapeutics, Inc. has filed a Follow-on Equity Offering.Jan 18+ 1 more updateChief Medical Officer recently bought US$189k worth of stock Dec 20Perspective Therapeutics, Inc. Announces First Patient Dosed in A Phase 1 Study Of212pb)Vmt-A-Net to Treat Refractory or Relapsed Neuroendocrine TumorsDec 07Perspective Therapeutics, Inc. Announces First Ever Human SPECT Imaging of Pb-212 with VMT-a-NET by Clinical Collaborators in GermanyNov 29+ 1 more updateNew major risk - Financial position Nov 20Perspective Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $50 million.Nov 19Third quarter 2023 earnings: EPS in line with expectations, revenues disappoint Nov 17Perspective Therapeutics, Inc. Announces First Patient Dosed in Phase 1/2A Study of [(212)Pb VMT-a-Net for Treatment of Advanced SSTR2-Positive Neuroendocrine TumorsNov 09Perspective Therapeutics, Inc. Announces Two Upcoming Investigator-Initiated TrialsOct 11Perspective Therapeutics, Inc. Announces Presentation of Positive Early Clinical Data for VMT-a-NET at 36th Annual Congress of European Association of Nuclear MedicineSep 13Perspective Therapeutics, Inc. Presents Positive Preclinical Alpha Particle Therapy Data at the World Molecular Imaging Congress 2023 and the 36th Annual Congress of the European Association of Nuclear MedicineSep 12Perspective Therapeutics, Inc., Annual General Meeting, Oct 06, 2023Aug 24New major risk - Financial position Aug 14Perspective Therapeutics, Inc. Announces First Patient Dosed in Phase 1/2a Dose Escalation Trial of VMT01 of its Targeted Alpha-Particle Therapy (TAT), for Treatment of MC1R-positive Metastatic MelanomaAug 12収支内訳Perspective Therapeutics の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。収益と収入の歴史NYSEAM:CATX 収益、費用、利益 ( )USD Millions日付収益収益G+A経費研究開発費31 Dec 251-10430030 Sep 251-10632230 Jun 251-9531231 Mar 251-8529231 Dec 241-7827030 Sep 242-5823130 Jun 241-5221131 Mar 242-5020131 Dec 231-3721130 Sep 23-1-1917030 Jun 231-1316031 Mar 233-614131 Dec 225-89230 Sep 2210-911330 Jun 220-66131 Mar 2211-69231 Dec 2111-69230 Sep 2110-58230 Jun 2110-37131 Mar 2110-47131 Dec 2010-37130 Sep 2010-37130 Jun 2010-38131 Mar 209-37131 Dec 198-47130 Sep 198-47130 Jun 197-57131 Mar 197-67231 Dec 187-77230 Sep 186-77230 Jun 186-77231 Mar 186-67131 Dec 175-67130 Sep 175-66130 Jun 175-66131 Mar 175-66131 Dec 164-55130 Sep 165-55130 Jun 165-55131 Mar 165-55131 Dec 155-45030 Sep 155-44130 Jun 155-441質の高い収益: CATXは現在利益が出ていません。利益率の向上: CATXは現在利益が出ていません。フリー・キャッシュフローと収益の比較過去の収益成長分析収益動向: CATXは利益が出ておらず、過去 5 年間で損失は年間62%の割合で増加しています。成長の加速: CATXの過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。収益対業界: CATXは利益が出ていないため、過去 1 年間の収益成長をBiotechs業界 ( 50.1% ) と比較することは困難です。株主資本利益率高いROE: CATXは現在利益が出ていないため、自己資本利益率 ( -50.06% ) はマイナスです。総資産利益率使用総資本利益率過去の好業績企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 、過去の業績が好調な企業。View Financial Health企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/04/30 06:03終値2026/04/30 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Perspective Therapeutics, Inc. 15 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。22 アナリスト機関Edward WooAscendiant Capital Markets LLCAlec StranahanBofA Global ResearchYuan ZhiB. Riley Securities, Inc.19 その他のアナリストを表示
Perspective Therapeutics Inc Presents Updated Interim Data of [212Pb]VMT-a-NET in Ongoing Phase 1/2A Clinical TrialApr 21
Perspective Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $174.99337 million.Feb 03+ 1 more update
Perspective Therapeutics Announces Acceptance of VMT-a-NET Data for Presentation At the Asco Gastrointestinal Cancers SymposiumDec 04
Perspective Therapeutics, Inc. Announces First Patient Dosed with PSV359 in the Second Cohort of a Phase 1/2a Study in Patients with FAP-A Positive Solid TumorsOct 03
Perspective Therapeutics, Inc. Progresses Dose Finding for [212Pb)VMT01 in Combination with Nivolumab in Its Ongoing Phase 1/2a Study of MC1R-Positive Metastatic MelanomaSep 15
Perspective Therapeutics, Inc. Appoints Maya Martinez-Davis to Board of Directors and as A Member of the Compensation Committee of the Board and the Nominations Committee, Effective September 03, 2025Sep 03
Perspective Therapeutics Announces Acceptance of VMT-a-NET Data for Presentation at the ESMO Congress 2025Jul 25
Perspective Therapeutics, Inc.(NYSEAM:CATX) dropped from Russell 3000E Growth IndexJun 30+ 4 more updates
Perspective Therapeutics, Inc. Commences Recruitment for VMT-a-NET in the Third Dose Escalation Cohort of its Ongoing Phase 1/2a Clinical TrialJun 22
Perspective Therapeutics, Inc. Highlights Updated Interim Data from its Ongoing Phase 1/2a Clinical Trial of [212Pb]VMT-a-NET at the 2025 ASCO Annual MeetingMay 31
Perspective Therapeutics, Inc. Announces First Patient Dosed with Psv359 in A Phase 1/2A Study in Patients with Fap-A Positive Solid TumorsApr 30
Perspective Therapeutics, Inc. Announces First Patient Dosed with212Pb)VMT01 Monotherapy at 1.5 mCi in a Phase 1/2a Study of MC1R-Positive Metastatic MelanomaApr 13
Perspective Therapeutics, Inc. Announces First Patient Dosed with Cm1R-Positive Metastatic MelanomaMar 18
Perspective Therapeutics, Inc. Continues to Pursue Dose Escalation of [212Pb) Vmt-A-Net in Its Ongoing Phase 1/2A Clinical Trial Based on Updated Interim Data Presented At the 2025 Asco Gastrointestinal Cancers SymposiumJan 24
Perspective Therapeutics, Inc. Announces Initial Results from its Ongoing Phase 1/2a Clinical Trial of [212Pb] VMT-a-NetNov 21
Perspective Therapeutics Begins Shipping Investigational Products from Radiopharmaceutical Manufacturing Facility in Somerset, New JerseyOct 16
Perspective Therapeutics to Advance Investigation of Potential First-In-Class Radiopharmaceutical Therapy (212Pb)Vmt01 Based on Data Presented At the 21St International Congress of the Society for Melanoma ResearchOct 11
Perspective Therapeutics Grants Fast Track Designation for VMT01 for the Diagnosis and Treatment of MC1R-Positive MelanomaSep 05
Perspective Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $49.868808 million.Aug 14+ 1 more update
Perspective Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $79.998535 million.May 25
Perspective Therapeutics, Inc. announced that it has received $87.409482 million in funding from Lantheus Holdings, Inc.Mar 07
Perspective Therapeutics, Inc. announced that it expects to receive $87.409482 million in funding from Lantheus Holdings, Inc. and other investorsMar 06
Perspective Therapeutics, Inc. (NYSEAM:CATX) completed the acquisition of Radiopharmaceutical Manufacturing Facility in Somerset, New Jersey from Progenics Pharmaceuticals, Inc.Mar 05
Perspective Therapeutics, Inc. announced that it has received $20.846671 million in funding from Lantheus Alpha Therapy, LLCJan 23
Perspective Therapeutics, Inc. announced that it expects to receive $20.8 million in fundingJan 19+ 1 more update
Perspective Therapeutics, Inc. Announces First Patient Dosed in A Phase 1 Study Of212pb)Vmt-A-Net to Treat Refractory or Relapsed Neuroendocrine TumorsDec 07
Perspective Therapeutics, Inc. Announces First Ever Human SPECT Imaging of Pb-212 with VMT-a-NET by Clinical Collaborators in GermanyNov 29+ 1 more update
Perspective Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $50 million.Nov 19
Perspective Therapeutics, Inc. Announces First Patient Dosed in Phase 1/2A Study of [(212)Pb VMT-a-Net for Treatment of Advanced SSTR2-Positive Neuroendocrine TumorsNov 09
Perspective Therapeutics, Inc. Announces Presentation of Positive Early Clinical Data for VMT-a-NET at 36th Annual Congress of European Association of Nuclear MedicineSep 13
Perspective Therapeutics, Inc. Presents Positive Preclinical Alpha Particle Therapy Data at the World Molecular Imaging Congress 2023 and the 36th Annual Congress of the European Association of Nuclear MedicineSep 12
Perspective Therapeutics, Inc. Announces First Patient Dosed in Phase 1/2a Dose Escalation Trial of VMT01 of its Targeted Alpha-Particle Therapy (TAT), for Treatment of MC1R-positive Metastatic MelanomaAug 12